β-Lactam plus aminoglycoside or fluoroquinolone combination versus β-lactam monotherapy for Pseudomonas aeruginosa infections: A meta-analysis

International Journal of Antimicrobial Agents

Volumn 41, Issue 4, 2013, Pages 301-310

  Vardakas, Konstantinos Z ^a,b   Tansarli, Giannoula S ^a   Bliziotis, Ioannis A ^a,b   Falagas, Matthew E ^a,b,c  

^a ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^b IASO GENERAL HOSPITAL   (Greece)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bacteraemia; Combination; Mortality; Pneumonia; Resistance

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAM ANTIBIOTIC; CEFEPIME; CEFOPERAZONE; CEFTAZIDIME; CILASTATIN PLUS IMIPENEM; GENTAMICIN; IMIPENEM; NETILMICIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOBRAMYCIN; VANCOMYCIN;

BACTEREMIA; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; COMPARATIVE EFFECTIVENESS; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; HUMAN; META ANALYSIS; MONOTHERAPY; MORTALITY; NEPHROTOXICITY; PRIORITY JOURNAL; PSEUDOMONAS INFECTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; REVIEW; SUPERINFECTION;

EID: 84875371294     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2012.12.006     Document Type: Short Survey

References (46)

1. S. Blot, K. Vandewoude, E. Hoste, and F. Colardyn Reappraisal of attributable mortality in critically ill patients with nosocomial bacteraemia involving Pseudomonas aeruginosa J Hosp Infect 53 2003 18 24
2. S. Osmon, S. Ward, V.J. Fraser, and M.H. Kollef Hospital mortality for patients with bacteremia due to Staphylococcus aureus or Pseudomonas aeruginosa Chest 125 2004 607 616
3. American Thoracic Society Infectious Diseases Society of America, Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia Am J Respir Crit Care Med 171 2005 388 416
4. H. Giamarellou Aminoglycosides plus β-lactams against Gram-negative organisms. Evaluation of in vitro synergy and chemical interactions Am J Med 80 1986 126 137
5. H. Giamarellou, N.P. Zissis, G. Tagari, and J. Bouzos In vitro synergistic activities of aminoglycosides and new β-lactams against multiresistant Pseudomonas aeruginosa Antimicrob Agents Chemother 25 1984 534 536
6. D.E. Johnson, and B. Thompson Efficacy of single-agent therapy with azlocillin, ticarcillin, and amikacin and β-lactam/amikacin combinations for treatment of Pseudomonas aeruginosa bacteremia in granulocytopenic rats Am J Med 80 1986 53 58
7. J.C. Pechère, B. Marchou, M. Michéa-Hamzehpour, and R. Auckenthaler Emergence of resistance after therapy with antibiotics used alone or combined in a murine model J Antimicrob Chemother 17 Suppl. A 1986 11 18
8. R. Marcus, M. Paul, H. Elphick, and L. Leibovici Clinical implications of β-lactam-aminoglycoside synergism: systematic review of randomised trials Int J Antimicrob Agents 37 2011 491 503
9. M. Paul, I. Benuri-Silbiger, K. Soares-Weiser, and L. Leibovici β Lactam monotherapy versus β lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials BMJ 328 2004 668
10. M. Paul, K. Soares-Weiser, and L. Leibovici β Lactam monotherapy versus β lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis BMJ 326 2003 1111
11. N. Safdar, J. Handelsman, and D.G. Maki Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis Lancet Infect Dis 4 2004 519 527
12. D. Moher, B. Pham, A. Jones, D.J. Cook, A.R. Jadad, and M. Moher Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 352 1998 609 613
13. I.A. Bliziotis, N. Petrosillo, A. Michalopoulos, G. Samonis, and M.E. Falagas Impact of definitive therapy with β-lactam monotherapy or combination with an aminoglycoside or a quinolone for Pseudomonas aeruginosa bacteremia PLoS One 6 2011 e26470
14. G.P. Bodey, L. Jadeja, and L. Elting Pseudomonas bacteremia. Retrospective analysis of 410 episodes Arch Intern Med 145 1985 1621 1629
15. I. Chatzinikolaou, D. Abi-Said, G.P. Bodey, K.V. Rolston, J.J. Tarrand, and G. Samonis Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: retrospective analysis of 245 episodes Arch Intern Med 160 2000 501 509
16. M. Chaudhary, S.M. Shrivastava, L. Varughese, and R. Sehgal Efficacy and safety evaluation of fixed dose combination of cefepime and amikacin in comparison with cefepime alone in treatment of nosocomial pneumonia patients Curr Clin Pharmacol 3 2008 118 122
17. A. Cometta, J.D. Baumgartner, D. Lew, W. Zimmerli, D. Pittet, and P. Chopart Prospective randomized comparison of imipenem monotherapy with imipenem plus netilmicin for treatment of severe infections in nonneutropenic patients Antimicrob Agents Chemother 38 1994 1309 1313
18. A. Del Favero, F. Menichetti, P. Martino, G. Bucaneve, A. Micozzi, and G. Gentile A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia Clin Infect Dis 33 2001 1295 1301
19. A. Endimiani, F. Luzzaro, B. Pini, G. Amicosante, G.M. Rossolini, and A.Q. Toniolo Pseudomonas aeruginosa bloodstream infections: risk factors and treatment outcome related to expression of the PER-1 extended-spectrum β-lactamase BMC Infect Dis 6 2006 52
20. V. Fainstein, G.P. Bodey, L. Elting, R. Bolivar, M.J. Keating, and K.B. McCredie A randomized study of ceftazidime compared to ceftazidime and tobramycin for the treatment of infections in cancer patients J Antimicrob Chemother 12 Suppl. A 1983 101 110
21. J. Garnacho-Montero, M. Sa-Borges, J. Sole-Violan, F. Barcenilla, A. Escoresca-Ortega, and M. Ochoa Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: an observational, multicenter study comparing monotherapy with combination antibiotic therapy Crit Care Med 35 2007 1888 1895
22. P.G. Jones, K.V. Rolston, V. Fainstein, L. Elting, R.S. Walters, and G.P. Bodey Aztreonam therapy in neutropenic patients with cancer Am J Med 81 1986 243 248
23. S. Kljucar, M. Heimesaat, E. von Pritzbuer, and K. Olms Ceftazidime with and without tobramycin versus azlocillin plus tobramycin in the therapy of bronchopulmonary infections in intensive care patients [in German] Infection 15 Suppl. 4 1987 S185 S191
24. A. Kuikka, and V.V. Valtonen Factors associated with improved outcome of Pseudomonas aeruginosa bacteremia in a Finnish university hospital Eur J Clin Microbiol Infect Dis 17 1998 701 708
25. A. Kumar, R. Zarychanski, B. Light, J. Parrillo, D. Maki, and D. Simon Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis Crit Care Med 38 2010 1773 1785
26. L. Leibovici, M. Paul, O. Poznanski, M. Drucker, Z. Samra, and H. Konigsberger Monotherapy versus β-lactam-aminoglycoside combination treatment for Gram-negative bacteremia: a prospective, observational study Antimicrob Agents Chemother 41 1997 1127 1133
27. M.H. Mendelson, A. Gurtman, S. Szabo, E. Neibart, B.R. Meyers, and M. Policar Pseudomonas aeruginosa bacteremia in patients with AIDS Clin Infect Dis 18 1994 886 895
28. S.T. Micek, A.E. Lloyd, D.J. Ritchie, R.M. Reichley, V.J. Fraser, and M.H. Kollef Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment Antimicrob Agents Chemother 49 2005 1306 1311
29. M. Piccart, J. Klastersky, F. Meunier, H. Lagast, Y. Van Laethem, and D. Weerts Single-drug versus combination empirical therapy for Gram-negative bacillary infections in febrile cancer patients with and without granulocytopenia Antimicrob Agents Chemother 26 1984 870 875
30. K.V. Rolston, P. Berkey, G.P. Bodey, E.J. Anaissie, N.M. Khardori, and J.H. Joshi A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients Arch Intern Med 152 1992 283 291
31. Todeschini G, Franchini M, Tecchio C, Meneghini V, Pizzolo G, Veneri D et al. Improved prognosis of Pseudomonas aeruginosa bacteremia in 127 consecutive neutropenic patients with hematologic malignancies. Int J Infect Dis 1998-1999;3:99-104.
32. A. Kumar, N. Safdar, S. Kethireddy, and D. Chateau A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: a meta-analytic/meta- regression study Crit Care Med 38 2010 1651 1664
33. A.P. Magiorakos, A. Srinivasan, R.B. Carey, Y. Carmeli, M.E. Falagas, and C.G. Giske Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance Clin Microbiol Infect 18 2012 268 281
34. W.K. Lau, D. Mercer, K.M. Itani, D.P. Nicolau, J.L. Kuti, and D. Mansfield Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection Antimicrob Agents Chemother 50 2006 3556 3561
35. T.P. Lodise Jr., B. Lomaestro, and G.L. Drusano Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy Clin Infect Dis 44 2007 357 363
36. L. Lorente, L. Lorenzo, M.M. Martin, A. Jiménez, and M.L. Mora Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to Gram-negative bacilli Ann Pharmacother 40 2006 219 223
37. G.W. Patel, N. Patel, A. Lat, K. Trombley, S. Enbawe, and K. Manor Outcomes of extended infusion piperacillin/tazobactam for documented Gram-negative infections Diagn Microbiol Infect Dis 64 2009 236 240
38. M.E. Falagas, G.S. Tansarli, K. Ikawa, and K.Z. Vardakas Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis Clin Infect Dis 56 2 2013 272 282
39. S.V. Bhat, A.Y. Peleg, T.P. Lodise Jr., K.A. Shutt, B. Capitano, and B.A. Potoski Failure of current cefepime breakpoints to predict clinical outcomes of bacteremia caused by Gram-negative organisms Antimicrob Agents Chemother 51 2007 4390 4395
40. R. Dagan, O. Abramson, E. Leibovitz, D. Greenberg, R. Lang, and S. Goshen Bacteriologic response to oral cephalosporins: are established susceptibility breakpoints appropriate in the case of acute otitis media? J Infect Dis 176 1997 1253 1259
41. C.M. Parry, H. Vinh, N.T. Chinh, J. Wain, J.I. Campbell, and T.T. Hien The influence of reduced susceptibility to fluoroquinolones in Salmonella enterica serovar Typhi on the clinical response to ofloxacin therapy PLoS Negl Trop Dis 5 2011 e1163
42. J. Rodríguez-Baño, M.D. Navarro, P. Retamar, E. Picón, and Á. Pascual Extended-Spectrum Beta-Lactamases-Red Española de Investigación en Patología Infecciosa/Grupo de Estudio de Infección Hospitalaria Group, β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts Clin Infect Dis 54 2012 167 174
43. M.E. Falagas, G.S. Tansarli, P.I. Rafailidis, A. Kapaskelis, and K.Z. Vardakas Impact of antibiotic MIC on infection outcome in patients with susceptible Gram-negative bacteria: a systematic review and meta-analysis Antimicrob Agents Chemother 56 2012 4214 4222
44. M.A. Aarts, J.N. Hancock, D. Heyland, R.S. McLeod, and J.C. Marshall Empiric antibiotic therapy for suspected ventilator-associated pneumonia: a systematic review and meta-analysis of randomized trials Crit Care Med 36 2008 108 117
45. P. Furno, G. Bucaneve, and A. Del Favero Monotherapy or aminoglycoside-containing combinations for empirical antibiotic treatment of febrile neutropenic patients: a meta-analysis Lancet Infect Dis 2 2002 231 242
46. I.A. Bliziotis, G. Samonis, K.Z. Vardakas, S. Chrysanthopoulou, and M.E. Falagas Effect of aminoglycoside and β-lactam combination therapy versus β-lactam monotherapy on the emergence of antimicrobial resistance: a meta-analysis of randomized, controlled trials Clin Infect Dis 41 2005 149 158